Contineum Therapeutics Inc. Class A Common Stock (CTNM)

FairStock Score: 37/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett/Graham investor, I start with what is knowable: Contineum is a 51-employee clinical-stage biopharma with lead assets PIPE-791 and PIPE-307. Filed figures show revenue of $50.0 million in fiscal 2023, net income of $22.7 million, then a swing to a net loss of $42.3 million in fiscal 2024 and $60.0 million in fiscal 2025. Recent quarters continue the pattern: in the quarter ended 2026-06-30, net loss was $15.2 million; in the quarter ended 2026-03-31, $14.5 million; in the quarter ended 2025-09-30, $12.8 million. There is no reported revenue in those filings. That is not a durable earnings stream; it is a pipeline financing story. The FairStock Lynch category is TURNAROUND — loss in the latest year after earlier profits — but the earlier profit did not persist. The balance sheet looks low-levered: D/E 0.03 and an Altman Z-Score of 10.87, both FairStock calculations. Yet trailing free cash flow is -$53.5 million, a -27.5% FCF yield, and Piotroski is 1/9. ROE is -28.00% and ROCE -19.15%. At the $8.42 close on 2026-10-13, market cap is $194.5 million; P/B is 1.32, while P/E is -4.90 because EPS is negative. The 52-week range is $8.10-$17.78, so the shares sit near the low. I see no proven moat—only clinical optionality. Graham would call this speculative until cash flows and approvals appear. Buffett would ask for demonstrated earning power, not hope. FairStock score 37/100 reinforces caution.

In plain English: Contineum Therapeutics is a small drug company that is testing experimental medicines for brain, pain, and immune conditions. It reported no recent revenue and lost $60.0 million in fiscal 2025, so the business looks weak on today's numbers. At $8.42 a share, the price is mostly a bet on future drug tests rather than current profits, and it does not look clearly cheap or expensive.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer